Abstract 126P
Background
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide and its incidence is steadily rising. Recently, immune-checkpoint inhibitors have revolutionized the management of HCC and combination of atezolizumab and bevacizumab has been shown to improve overall survival. We performed a molecular and cellular characterization of the tumour microenvironment that plays a crucial role in the development of HCC.
Methods
We performed a sequential treatment with anti-PD-L1 atezolizumab in combination with anti-VEGF bevacizumab for 6 days followed by tyrosine kinase inhibitor (TKI) lenvatinib for additional 6 days on HCC cell lines (HuH7 and SNU449) and then we measured the resulted effect by MTT assay for cell proliferation. After treatments we investigated tumour microenvironment (vimentin, cadherin) and immune markers (PD-L1, CTLA4 and cytokines) on HuH7 and SNU449 cells co-coltured with PBMCs (peripheral blood mononuclear cells) through RT-PCR.
Results
Combination of atezolizumab and bevacizumab followed by lenvatinib shows a reduction of cell growth, we observed a decrease in cell proliferation of 53.2 and 58.1 % for HuH7 and SNU449 respectively. This result is enhanced in cell co-coltures with PBMCs, in which cell viability is significantly reduced reaching value of 37.5 and 38.2 % for HuH7 and SNU449. We observed a decrease of PD-L1 and CTLA4 and a parallel increase of IFNγ, GRZb, IL-6 and IL1β, all cytokines able to create favourable microenvironment for inflammatory and immune response. The effect is accompanied by a functional change in favour of EMT blockade with increased cadherin and reduced vimentin expression (8.26- and 0.5-fold increase values, for cadherin and vimentin respectively, compared to untreated control) after sequential treatments.
Conclusions
Our work could provide good perspectives on predictability and sensitivity to new drug combination strategies in patients with HCC resistant to immune blockade. We aim to confirm the effect of the treatment also in ex vivo human spheroids and patients derived lymphocytes co-coltures, to verify the possible synergism of PD-L1 and VEGF inhibition on cytokine secretion profile.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract